The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations
Open accessAbstract
Inhibition of WEE1, a key regulator of the G2/M checkpoint of the cell cycle, induces apoptosis by initiating mitosis without repairing DNA damage. However, the effects of WEE1 inhibitors on the tumor immune microenvironment in colorectal cancer (CRC) remain unclear. Here, we investigated the association between WEE1 expression and CRC clinicopathological features using surgically resected CRC specimens and assessed the antitumor effects of a WEE1 inhibitor using CRC cell lines and orthotopic transplantation mouse models. WEE1 expression was not correlated with the clinicopathological features of CRC. The WEE1 inhibitor suppressed cell proliferation in a concentration-dependent manner in all CRC cell lines. It also increased the percentage of cells in the G2/M phase and apoptotic cells, especially in cell lines with p53 mutations, but did not alter these cell percentages in most p53 wild-type cell lines. In the orthotopic mouse model of CRC, tumor volume was significantly reduced in the WEE1 inhibitor-treated group compared to that in the control group. RNA sequencing and immunohistochemistry analyses of mouse tumors revealed that treatment with the WEE1 inhibitor activated tumor immunity and suppressed stromal reactions. These results demonstrate the potential antitumor effects of WEE1 inhibitors in CRC, particularly in patients with p53 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A WEE1 inhibitor was recently reported to exert anticancer effects in CRC cells, particularly in those with TP53 mutations [140].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
Kanda, Y. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.244 · Cited by 18,767 · cited 1×
“All statistical analyses were conducted using the EZR software (version 1.60, Saitama Medical Centre, Jichi Medical University, Saitama, Japan) [28].”
MethodInfluentialTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Visualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481 · cited 1×
“Using the University of California, Santa Cruz (UCSC) Cancer Genomics Browser UCSC Xena (https://xena.ucsc.edu/) is an analytical tool used to explore functional genomic datasets and to correlate genomic and phenotypic variables [27].”
MethodTyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis
Gould, K. L., & Nurse, P. (1989) · Nature · doi:10.1038/342039a0 · Cited by 1,218 · cited 1×
“WEE1 functions by phosphorylating 15 tyrosine residues of cyclin-dependent kinase 1 (CDK1), thereby inhibiting the activation of the cyclin B–CDK1 complex and the transition from the G2 phase to the M phase of the cell cycle [1,2].”
BackgroundSuppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 1×
“Stromal components have been reported to act as barriers to immune cell infiltration in various carcinomas [36–38].”
BackgroundEpigenetic and genetic features of 24 colon cancer cell lines
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.35 · Cited by 910
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, I. M., & Kurman, R. J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.85 · Cited by 513 · cited 1×
“Furthermore, we classified diffuse strong, nested, and negative as p53 mutations and mosaic, sporadic, and diffuse weak as p53 wild types, according to previous reports [25,26].”
ResultTargeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408 · cited 1×
“WEE1 regulates the initiation of mitosis and arrests the cell cycle in the G2 phase, allowing for DNA repair [3].”
BackgroundCell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388 · cited 1×
“…of genomic instability and apoptosis. p53 and KRAS play crucial roles in cell cycle regulation. p53 is a central regulator of the G1/S checkpoint [4], whereas KRAS mutations induce genomic instability by promoting the transition to the S phase and inducing cell division through sustained CDK2…”
BackgroundMulti-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Berg, K. C. G., Eide, P. W., Eilertsen, I. A., Johannessen, B., Bruun, J., Danielsen, S. A., Bjørnslett, M., Meza-Zepeda, L. A., Eknæs, M., Lind, G. E., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0691-y · Cited by 382 · cited 2×
“Additionally, in both mouse colon cancer cell lines (CT26 and MC38), the expression level of WEE1 tended to be higher than that in normal The gene mutation statuses (p53 , KRAS , and BRAF ) and MSI of each cell line are shown in Table 4 [29,30]. colonic mucosa.”
BackgroundREGULATORY GENES CONTROLLING MITOSIS IN THE FISSION YEAST SCHIZOSACCHAROMYCES POMBE
Nurse, P., & Thuriaux, P. (1980) · Genetics · doi:10.1093/genetics/96.3.627 · Cited by 369
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351 · cited 1×
“In contrast, cases with KRAS mutation tend to have a worse prognosis, consistent with previous reports [32].”
ResultForced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327 · cited 1×
“In contrast, in non-small-cell lung cancer [20] and malignant melanoma [21], WEE1 is more highly expressed in low-grade lesions than in high-grade lesions, and the deletion of WEE1 has been reported to be an indicator of poor prognosis.”
BackgroundDNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322 · cited 1×
“Previous reports [49,50] have suggested that WEE1 inhibitors may act in a cancer-specific manner.”
BackgroundDo, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322 · cited 1×
“Furthermore, a few clinical trials have shown no response to WEE1 inhibitors as single agents in patients with solid tumors harboring p53 mutations [15].”
BackgroundA WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Ghelli Luserna di Rorà, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00959-2 · Cited by 314
Beck, H., Nähse-Kumpf, V., Larsen, M. S. Y., O'Hanlon, K. A., Patzke, S., Holmberg, C., Mejlvang, J., Groth, A., Nielsen, O., Syljuåsen, R. G., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00412-12 · Cited by 306 · cited 1×
“This finding is consistent with those of previous studies [42,43] showing that WEE1 regulates the DNA replication rate by suppressing CDK2 activity at the intra-S checkpoint, thereby preventing replication from being initiated from numerous replication origins, resulting in excessive replication…”
ResultMir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Regulation of the anti-tumour immune response by cancer-associated fibroblasts
Harper, J., & Sainson, R. C. A. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.005 · Cited by 268 · cited 1×
“Stromal components have been reported to act as barriers to immune cell infiltration in various carcinomas [36–38].”
BackgroundHirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237 · cited 2×
“The association between the effects of WEE1 inhibitors and p53 or KRAS mutation status has been investigated in various cancers; however, some studies have highlighted the correlation between p53 or KRAS mutation status and the effects of WEE1 inhibitors [7], whereas others have not [13].”
BackgroundTargeting the replication stress response in cancer
Forment, J. V., & O’Connor, M. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.005 · Cited by 170 · cited 1×
“Previous reports [49,50] have suggested that WEE1 inhibitors may act in a cancer-specific manner.”
BackgroundTaniguchi, H., Caeser, R., Chavan, S. S., Zhan, Y. A., Chow, A. T., Manoj, P., Uddin, F. Z., Kitai, H., Qu, R., Hayatt, O., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110814 · Cited by 146 · cited 1×
“WEE1 inhibitors have been reported to activate the cytosolic-DNA sensing, interferon, and JAK-STAT pathways, thereby enhancing tumor immunity through CD8+ T cell infiltration, increased cytokine and chemokine signaling, and increased PD-L1 expression [24,35].”
BackgroundThe clinical significance of Cyclin B1 and Wee1 expression innon-small-cell lung cancer
Yoshida, T., Tanaka, S., Mogi, A., Shitara, Y., & Kuwano, H. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh073 · Cited by 144 · cited 1×
“In contrast, in non-small-cell lung cancer [20] and malignant melanoma [21], WEE1 is more highly expressed in low-grade lesions than in high-grade lesions, and the deletion of WEE1 has been reported to be an indicator of poor prognosis.”
BackgroundMagnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K. R., Slipicevic, A., & Flørenes, V. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038254 · Cited by 144
Linden, A. A. V., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L. A., Korch, C. T., Reigan, P., & Porter, C. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0424 · Cited by 130
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Kreahling, J. M., Gemmer, J. Y., Reed, D. R., Letson, D. G., Bui, M. M., & Altiok, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0529 · Cited by 125 · cited 1×
“In contrast, in leukemia, lung cancer [13], and sarcoma [14], the efficacy of WEE1 inhibitors does not appear to be related to the presence of p53 mutations.”
BackgroundSeligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., Richman, S. D., Butler, R., Domingo, E., Blake, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01435 · Cited by 124 · cited 3×
“…particular, few reports have examined this for CRC, and the only report on the efficacy of WEE1 inhibitors as single agents is the report on the clinical trial [9], which did not examine the difference in the efficacy of WEE1 inhibitors depending on the presence or absence of p53 or KRAS mutations.”
BackgroundInfluentialMurrow, L. M., Garimella, S. V., Jones, T. L., Caplen, N. J., & Lipkowitz, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0571-2 · Cited by 92 · cited 1×
“WEE1 overexpression has been reported in various cancer types, including malignant melanoma [16], breast cancer [17], ovarian cancer [18], and glioma [19].”
BackgroundWEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
Guo, E., Xiao, R., Wu, Y., Lu, F., Liu, C., Yang, B., Li, X., Fu, Y., Wang, Z., Yuan, L., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210789 · Cited by 83 · cited 2×
“WEE1 inhibitors have been reported to activate the cytosolic-DNA sensing, interferon, and JAK-STAT pathways, thereby enhancing tumor immunity through CD8+ T cell infiltration, increased cytokine and chemokine signaling, and increased PD-L1 expression [24,35].”
BackgroundSlipicevic, A., Holth, A., Hellesylt, E., Trope, C. G., Davidson, B., & Flørenes, V. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.102 · Cited by 82 · cited 1×
“WEE1 overexpression has been reported in various cancer types, including malignant melanoma [16], breast cancer [17], ovarian cancer [18], and glioma [19].”
BackgroundVisconti, R., Palazzo, L., Monica, R. D., & Grieco, D. (2012) · Nature Communications · doi:10.1038/ncomms1886 · Cited by 68 · cited 1×
“Therefore, WEE1 inhibition has been shown to promote the transition to the M phase and the progression of mitosis while inhibiting the termination of the M phase, resulting in M phase prolongation [41].”
BackgroundWEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity
Elbæk, C. R., Petrosius, V., Benada, J., Erichsen, L., Damgaard, R. B., & Sørensen, C. S. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110261 · Cited by 64 · cited 1×
“This finding is consistent with those of previous studies [42,43] showing that WEE1 regulates the DNA replication rate by suppressing CDK2 activity at the intra-S checkpoint, thereby preventing replication from being initiated from numerous replication origins, resulting in excessive replication…”
ResultSynthetic lethality in KRas-driven cancer cells created by glutamine deprivation
Mukhopadhyay, S., Saqcena, M., & Foster, D. A. (2015) · Oncoscience · doi:10.18632/oncoscience.253 · Cited by 61 · cited 1×
“WEE1 inhibition has also been reported to affect glutamine metabolism, with reports that inhibition of WEE1 suppresses the glycolytic system, increasing dependence on glutamine metabolism [46] and that oncogenic KRAS regulates cell cycle checkpoints and glutamine metabolism [47].”
BackgroundWeisberg, E., Nonami, A., Chen, Z., Liu, F., Zhang, J., Sattler, M., Nelson, E. A., Cowens, K. B., Christie, A. L., Mitsiades, C. S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.149 · Cited by 53 · cited 1×
“Moreover, several other clinical trials have shown that WEE1 inhibitors, in combination with other agents, are effective against pancreatic cancer [10], non-small-cell lung cancer [11], and leukemia [12] with KRAS mutations.”
BackgroundA syngeneic MC38 orthotopic mouse model of colorectal cancer metastasis
Greenlee, J. D., & King, M. R. (2022) · Biology Methods and Protocols · doi:10.1093/biomethods/bpac024 · Cited by 41
Sharma, A. K., Madhunapantula, S. V., Gowda, R., Berg, A. S., Neves, R. I., & Robertson, G. P. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.019 · Cited by 38 · cited 1×
“In a report on melanoma, the inhibition of V600E BRAF decreased WEE1 expression, suggesting that WEE1 is located downstream of V600E BRAF in the MAPK signaling cascade [31] and that mutations in BRAF activate the MAPK pathway and increase WEE1 expression.”
BackgroundKu, B. M., Bae, Y.-H., Koh, J., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18728 · Cited by 37 · cited 1×
“A previous study on non-small-cell lung cancer with KRAS mutations reported that induction of DNA damage and apoptosis by WEE1 inhibitors occurs only in the presence of p53 mutations because the PI3K–AKT pathway is inhibited by WEE1 inhibitors only in the presence of p53 mutations [33].”
BackgroundThe metabolic importance of the glutaminase II pathway in normal and cancerous cells
Dorai, T., Pinto, J. T., Denton, T. T., Krasnikov, B. F., & Cooper, A. J. L. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.114083 · Cited by 37 · cited 1×
“…affects the tumor stroma, and it has been reported that the glutamine-metabolizing enzyme GLS1 promotes cancer growth via autophagy in the tumor stroma [48], and it is possible that the effect of WEE1 inhibitors on glutamine metabolism is involved in the suppression of the stromal reaction.”
BackgroundYin, Y., Shen, Q., Tao, R., Chang, W., Li, R., Xie, G., Liu, W., Zhang, P., & Tao, K. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8230 · Cited by 36 · cited 1×
“WEE1 inhibitors have been reported to enhance the efficacy of other chemotherapeutic agents such as 5-FU [7] and irinotecan [8] in colorectal cancer (CRC) with p53 mutations.”
BackgroundKoh, S. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110310 · Cited by 36 · cited 1×
“These findings of the present study align with those of a few recent studies, which reported that WEE1 is involved in controlling the termination of the M phase and inhibiting its progression to the M phase at the G2/M checkpoint [39,40].”
ResultWEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia
Hu, J., Wang, T., Xu, J., Wu, S., Wang, L., Su, H., Jiang, J., Yue, M., Wang, J., Wang, D., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.231126 · Cited by 35 · cited 1×
“WEE1 inhibition has also been reported to affect glutamine metabolism, with reports that inhibition of WEE1 suppresses the glycolytic system, increasing dependence on glutamine metabolism [46] and that oncogenic KRAS regulates cell cycle checkpoints and glutamine metabolism [47].”
BackgroundFikaris, A. J., Lewis, A. E., Abulaiti, A., Tsygankova, O. M., & Meinkoth, J. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606737200 · Cited by 33 · cited 1×
“…and apoptosis. p53 and KRAS play crucial roles in cell cycle regulation. p53 is a central regulator of the G1/S checkpoint [4], whereas KRAS mutations induce genomic instability by promoting the transition to the S phase and inducing cell division through sustained CDK2 activation [5,6].”
BackgroundDiehl, J. N., Klomp, J. E., Snare, K. R., Hibshman, P. S., Blake, D. R., Kaiser, Z. D., Gilbert, T. S. K., Baldelli, E., Pierobon, M., Papke, B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101335 · Cited by 32 · cited 1×
“Moreover, several other clinical trials have shown that WEE1 inhibitors, in combination with other agents, are effective against pancreatic cancer [10], non-small-cell lung cancer [11], and leukemia [12] with KRAS mutations.”
BackgroundUpregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer
Ge, X., Wu, F., Li, W., Zhu, X., Liu, J.-W., & Wang, B. (2017) · Oncology Letters · doi:10.3892/ol.2017.5984 · Cited by 30 · cited 1×
“Regarding WEE1 expression and prognosis in CRC, studies have shown increased metastases, disease progression, and poor prognosis in cases with high WEE1 expression [22], while others suggest no correlation with prognosis [23], rendering it a controversial topic.”
BackgroundWee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Caiola, E., Frapolli, R., Tomanelli, M., Valerio, R., Iezzi, A., Garassino, M. C., Broggini, M., & Marabese, M. (2018) · Scientific Reports · doi:10.1038/s41598-017-18900-y · Cited by 29 · cited 1×
“Moreover, several other clinical trials have shown that WEE1 inhibitors, in combination with other agents, are effective against pancreatic cancer [10], non-small-cell lung cancer [11], and leukemia [12] with KRAS mutations.”
BackgroundSelective Killing of RAS-Malignant Tissues by Exploiting Oncogene-Induced DNA Damage
Murcia, L., Clemente‐Ruiz, M., Pierre-Elies, P., Royou, A., & Milán, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.004 · Cited by 26 · cited 1×
“…and apoptosis. p53 and KRAS play crucial roles in cell cycle regulation. p53 is a central regulator of the G1/S checkpoint [4], whereas KRAS mutations induce genomic instability by promoting the transition to the S phase and inducing cell division through sustained CDK2 activation [5,6].”
BackgroundIdentification of WEE1 as a target to make AKT inhibition more effective in melanoma
Kuzu, O. F., Gowda, R., Sharma, A. K., Noory, M. A., Kardos, G. R., Madhunapantula, S. V., Drabick, J. J., & Robertson, G. P. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1360446 · Cited by 21 · cited 1×
“Overactivation of AKT suppresses the DNA damage response, inhibits the apoptosis-inducing pathway, and promotes cell cycle progression, allowing cells with unrepaired DNA damage to continue dividing without being removed by apoptosis [34].”
BackgroundExpression and clinical significance of Wee1 in colorectal cancer
Egeland, E. V., Flatmark, K., Nesland, J. M., Flørenes, V. A., Mælandsmo, G. M., & Boye, K. (2016) · Tumor Biology · doi:10.1007/s13277-016-5081-3 · Cited by 20 · cited 1×
“Regarding WEE1 expression and prognosis in CRC, studies have shown increased metastases, disease progression, and poor prognosis in cases with high WEE1 expression [22], while others suggest no correlation with prognosis [23], rendering it a controversial topic.”
BackgroundHong, K.-S., Kim, H.-S., Kim, S.-H., Lim, D.-J., Park, J. Y., & Kim, S.-D. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.12.074 · Cited by 13 · cited 1×
“Hypoxia has been reported to enhance WEE1 expression [44] and induce DNA double-strand breaks, leading to cell cycle arrest at the G2 phase and activation of the DNA damage response (DDR) pathway [45].”
BackgroundWEE1 inhibition enhances sensitivity to hypoxia/reoxygenation in HeLa cells
Goto, T., Homma, H., Kaida, A., & Miura, M. (2019) · Journal of Radiation Research · doi:10.1093/jrr/rrz045 · Cited by 3 · cited 1×
“Hypoxia has been reported to enhance WEE1 expression [44] and induce DNA double-strand breaks, leading to cell cycle arrest at the G2 phase and activation of the DNA damage response (DDR) pathway [45].”
Background
Research works printed but not linked: 1
- Yokota, 2016, Evaluation of p53 Protein Overexpression by Immunohistochemistry―Study based on Gene Mutation Analysis, Niigata Igakukai Zassi, 130, 109
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“A WEE1 inhibitor was recently reported to exert anticancer effects in CRC cells, particularly in those with TP53 mutations [140].”
Mesenchymal stem cell therapy for premature ovarian insufficiency: progress and challenges
Shao, Z., Liang, L., Xue, Y., Zhu, T., & Wen, Q. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-01976-4 · Cited by 6
“Novel Wee1 inhibitors (e.g. adavosertib) arrest tumour cells in an unscheduled S phase but appear less toxic to quiescent ovarian follicles, although formal reproductive-toxicology data are pending [140, 141].”
Pham, A. T., Yuan, F., Nagathihalli, N. S., & Dosch, A. R. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101309 · Cited by 5
Liu, Y., Wei, X., Chen, N., & Wang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-03509-9 · Cited by 4
Özdemir, G., & Kaplan, H. M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070574 · Cited by 3
“The upregulation of WEE1, a key cell cycle regulator, suggests Tempol induces G2/M cell cycle arrest to allow for DNA repair [39].”
Metadata
- Authors
- Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S.
- Affiliations
- Hiroshima University Hospital (JP)
- Corresponding author
- Yuge, Ryo
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-09-12
- Volume
- 16
- Issue
- 18
- Pages
- 3136
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11429655
- OpenAlex
- W4402486551
- Cited by
- 12
- References
- 52
- Citations by year
- 2026: 9 · 2025: 3
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- WEE1 inhibitor, adavosertib, colorectal cancer, TP53 mutation, G2/M checkpoint, DNA damage-induced apoptosis, tumor immune microenvironment, antitumor immunity, tumor stroma, cell proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.